<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00865462</url>
  </required_header>
  <id_info>
    <org_study_id>04-0646-004</org_study_id>
    <nct_id>NCT00865462</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions</brief_title>
  <official_title>A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion XL Tablets Formulation in Normal, Healthy Man Following a Standard Meal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the rate and extent of absorption of Abrika Bupropion
      150 mg XL Tablet to that of Wellbutrin XL® 150 mg Tablet after a single, one-tablet dose in
      subjects fed a standard meal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design.

      Official Title: A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study
      of Bupropion XL Tablets Formulation in Normal, Healthy Man Following a Standard Meal

      Further study details as provided by Actavis Elizabeth LLC:

      Primary Outcome Measures:

      Rate and Extend of Absorption
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abrika Bupropion 150 mg XL Tablet, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wellbutrin XL® 150 mg Tablet, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abrika Bupropion 150 mg XL Tablet, single dose</intervention_name>
    <description>A: Experimental Subjects received Abrika formulated products under fed conditions</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Bupropion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Wellbutrin XL® 150 mg Tablet, single dose</intervention_name>
    <description>B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Bupropion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is the individual a healthy, normal adult man who volunteers to participate?

          -  Is he 18-45 years of age, inclusive?

          -  Is his BMI ≤30?

          -  Is he considered reliable and capable of understanding his responsibility and role in
             the study?

          -  Has he provided written informed consent? A no answer to any of the above questions
             indicates that the individual is ineligible for enrollment

        Exclusion Criteria:

          -  Does the individual have a history of allergy or hypersensitivity to bupropion, milk
             or eggs?

          -  Does he smoke more than 25 cigarettes/day?

          -  Is he unable to refrain from smoking during the period beginning two hours before and
             ending four hours after study drug administration?

          -  Does he have a history of seizure, cranial trauma, or other predisposition to seizure?

          -  Does he have clinically significant laboratory abnormalities that would interfere with
             the conduct or interpretation of the study or jeopardize his safety?

          -  Does he have significant history or clinical evidence of auto-immune, cardiovascular,
             gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing
             infection, pancreatic, renal or other diseases, conditions or surgeries that would
             interfere with the conduct or interpretation of the study or jeopardize his safety?

          -  Does he have serious psychological illness?

          -  Does he have significant history (within the past six months) or clinical evidence of
             alcohol or drug abuse?

          -  Does he have a positive urine drug screen or saliva alcohol screen, or a positive
             HIV-l, or hepatitis B or C screen?

          -  Is he unable to refrain from the use of alcohol or xanthine-containing foods or
             beverages during periods beginning 24 and 48 hours, respectively, prior to study drug
             administration and ending when the last blood sample has been taken?

          -  Has he used any prescription drug during the 14-day period prior to study initiation
             (except for topical products without systemic absorption), or any OTC drug during the
             72-hour period preceding study initiation?

          -  Is he unable to refrain from the use of all concomitant medications during the study?

          -  Has he donated or lost blood, or participated in a clinical study which involved the
             withdrawal of a large volume of blood (480 mL or more), during the six week period
             preceding study initiation?

          -  Has he donated plasma during the two week period preceding study initiation?

          -  Has he received an investigational drug during the 30 day period preceding study
             initiation? A yes answer to any of the above questions indicates that the individual
             is ineligible for enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio R. Pizarro,, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC Ft. Myers, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC Ft. Myers, Inc.</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://chem.sis.nlm.nih.gov/chemidplus/ProxyServlet?QV1=BUPROPION&amp;QO1=%3D&amp;QF1=Name&amp;objectHandle=Search&amp;actionHandle=searchChemIdLite&amp;responseHandle=JSP&amp;nextPage=jsp%2Fchemidlite%2FChemidDataview.jsp</url>
    <description>BUPROPION</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2009</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Meena Venugopal, Director, Clinical R&amp;D</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

